Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Covid-19 Vaccine Responsiveness in Patients With Multiple Myeloma and Waldenstrom's Macroglobulinemia

NCT04830046 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT04830046
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04830046 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Covid-19 Vaccine Responsiveness in Patients With Multiple Myeloma and Waldenstrom's Macroglobulinemia
Lead sponsor
Massachusetts General Hospital
Phase
Observational
Overall status
Completed
Start date
April 15, 2021
Completion date
September 14, 2022
Enrollment
146 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid19, immune system disorder, multiple myeloma, waldenstrom macroglobulinemia